前列地尔联合生长抑素治疗重症急性胰腺炎的Meta分析

发布时间：2018-07-23 17:49

【摘要】：目的系统性评价前列地尔联合生长抑素治疗重症急性胰腺炎的疗效和安全性。方法检索PubMed、Cochrane library、Web of Science、万方数据库、中国知网数据库、中国生物医学数据库,检索时限均设定为各数据库建库至2015年11月,收集所有前列地尔联合生长抑素治疗重症急性胰腺炎的随机对照试验,应用RevMan 5.3软件对数据进行Meta分析。结果纳入11篇文献,共927例患者。Meta分析结果显示:与对照组相比,前列地尔联合生长抑素治疗组可以显著提高总有效率[OR=5.45,95%CI(3.48,8.52),P0.01],改善临床症状缓解时间[均数差(MD)=-15.20,95%CI(-18.17,-12.23),P0.01],血淀粉酶[MD=-26.59,95%CI(-29.85,-23.34),P0.01],血C反应蛋白[MD=-23.95,95%CI(-27.68,-20.22),P0.01],血白细胞介素-6[MD=-12.40,95%CI(-15.69,-9.11),P0.01],组间比较差异均有统计学意义。此外,不良反应发生率较低。结论在传统治疗基础上加用前列地尔联合生长抑素可以有效提高重症急性胰腺炎的治疗效果,且安全性高,值得临床推广。
[Abstract]:Objective to evaluate the efficacy and safety of alprostadil combined with somatostatin in the treatment of severe acute pancreatitis. Methods We searched PubMedus Cochrane libraryweb of Science, Wanfang Database, China knowledge Web Database and Chinese Biomedical Database. The searching time limit was set up until November 2015. All the randomized controlled trials of alprostadil combined with somatostatin in the treatment of severe acute pancreatitis were collected. The data were analyzed by Meta using RevMan 5.3 software. Results A total of 927 patients were included in 11 articles. The results of Meta-analysis showed that: compared with the control group, 鍓嶅垪鍦板皵鑱斿悎鐢熼暱鎶戠礌娌荤枟缁勫彲浠ユ樉钁楁彁楂樻，

本文编号：2140169